Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 12, 2016

Study Completion Date

June 12, 2016

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Capecitabine and aflibercept

"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."

Trial Locations (2)

23502

Virginia Oncology Associates, Norfolk

27710

Duke Cancer Center, Duke University Medical Center, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

John Strickler, M.D.

OTHER